Safety, Pharmacokinetics, and Pharmacodynamics of ASP3662, a Novel 11β‐Hydroxysteroid Dehydrogenase Type 1 Inhibitor, in Healthy Young and Elderly Subjects

• Váldodahkkit: Susan Bellaire (Dahkki), Mark Walzer (Dahkki), Tianli Wang (Dahkki), Walter Krauwinkel (Dahkki), Nancy Yuan (Dahkki), Gerard J. Marek (Dahkki)
• Materiálatiipa: Girji
• Almmustuhtton: Wiley, 2019-05-01T00:00:00Z.
• Fáttát: article
• Liŋkkat: Connect to this object online.

Inhibition of the enzyme 11β‐hydroxysteroid dehydrogenase type 1 (11β‐HSD1) represents a potential mechanism for improving pain conditions. ASP3662 is a potent and selective inhibitor of 11β‐HSD1. Two phase I clinical studies were conducted to assess the safety, tolerability, pharmacokinetics (PKs),...